FDA expands a bladder cancer drug to patients whose papillary tumors resist standard treatment

Oct. 14, 2026 — The Food and Drug Administration expanded approval of Anktiva, given with the standard immunotherapy BCG, to adults with high-grade papillary-only bladder cancer that has not reached the bladder muscle and has not responded to BCG, the agency said. It is the first approved treatment for that group, the agency said. The FDA based the decision on evidence from an earlier approval in a related form, carcinoma in situ.

The wall: Trial results specific to papillary-only disease were not in the release.

Tier: Confirmed (based on the FDA's release)

Sources

• U.S. Food and Drug Administration, FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer (Oct. 14, 2026)

health

This newsfeed was produced and brought to you by Temporal Data Dynamics Technology. For more information, visit temporaldatadynamics.com.